Cardiovascular metabolic syndrome: Mediators involved in the pathophysiology from obesity to coronary heart disease

Biomarkers in Medicine

Volumn 6, Issue 1, 2012, Pages 35-52

  Roos, Cornelis J ^a,b   Quax, Paul H A ^a,c   Jukema, J Wouter ^a,b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c Einthoven Laboratory of Experimental Vascular Medicine   (Netherlands)

Author keywords

adipokine; atherosclerosis; biomarker; C reactive protein; coronary artery disease; cytokine; diabetes mellitus; inflammation; metabolic syndrome; obesity

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; BIOLOGICAL MARKER; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; PENTRAXIN 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; APOPTOSIS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; OBESITY;

EID: 84856605623     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.105     Document Type: Review

References (137)

1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes.(Lond.) 32(9), 1431-1437 (2008).
2. Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch. Cardiovasc. Dis. 104(3), 178-188 (2011).
3. Dent TH. Predicting the risk of coronary heart disease I. The use of conventional risk markers. Atherosclerosis 213(2), 345-351 (2010).
4. Dent TH. Predicting the risk of coronary heart disease. II: the role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction. Atherosclerosis 213(2), 352-362 (2010).
5. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111(11), 1448-1454 (2005). (Pubitemid 40396812)
6. Espinola-Klein C, Gori T, Blankenberg S, Munzel T. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front. Biosci. 16, 1663-1674 (2011).
7. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29(24), 2959-2971 (2008).
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685-1695 (2005).
9. Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther. 87(4), 407-416 (2010).
10. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes. Metab. 9(3), 218-232 (2007). (Pubitemid 46502040)
11. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab. 3(1), 46-56 (2007). (Pubitemid 46006612)
12. Otto TC, Lane MD. Adipose development: from stem cell to adipocyte. Crit. Rev. Biochem. Mol. Biol. 40(4), 229-242 (2005). (Pubitemid 41140883)
13. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J. Physiol. Pharmacol. 57(4), 505-528 (2006). (Pubitemid 46096102)
14. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol. 25(10), 2062-2068 (2005). (Pubitemid 41416301)
15. Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 27(1), 84-91 (2007). (Pubitemid 46370478)
16. Surmi BK, Hasty AH. The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascul. Pharmacol. 52(1-2), 27-36 (2010).
17. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280(5), E745-E751 (2001).
18. Stephens JW, Khanolkar MP, Bain SC. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 202(2), 321-329 (2009).
19. Dandona P, Mohanty P, Hamouda W, et al. Inhibitory effect of a two day fast on reactive oxygen species (ROS) generation by leucocytes and plasma ortho-tyrosine and meta-tyrosine concentrations. J. Clin. Endocrinol. Metab. 86(6), 2899-2902 (2001). (Pubitemid 32545759)
20. Mohanty P, Ghanim H, Hamouda W, et al. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am. J. Clin. Nutr. 75(4), 767-772 (2002). (Pubitemid 34250692)
21. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17(1), 24-38 (2003). (Pubitemid 36410972)
22. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99(2), 224-229 (1999). (Pubitemid 29056363)
23. Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm. 2010, 174341 (2010).
24. Thomas GD, Zhang W, Victor RG. Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension. JAMA 285(16), 2055-2057 (2001). (Pubitemid 32367811)
25. Chapman MJ, Sposito AC. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacol. Ther. 117(3), 354-373 (2008).
26. Martens FM, Rabelink TJ, op 't Roodt J, de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur. Heart J. 27(13), 1605-1609 (2006). (Pubitemid 43954922)
27. Vidal F, Colome C, Martinez-Gonzalez J, Badimon L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. Eur. J. Biochem. 252(3), 378-384 (1998). (Pubitemid 28156861)
28. Sydow K, Mondon CE, Cooke JP. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc. Med. 10(Suppl. 1), S35-S43 (2005). (Pubitemid 43137266)
29. Potdar S, Kavdia M. NO/peroxynitrite dynamics of high glucose-exposed HUVECs: chemiluminescent measurement and computational model. Microvasc. Res. 78(2), 191-198 (2009).
30. Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int. J. Clin. Pract. 62(7), 1087-1095 (2008). (Pubitemid 351793598)
31. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest. 93(6), 2438-2446 (1994). (Pubitemid 24177157)
32. Bezaire V, Mairal A, Ribet C, et al. Contribution of adipose triglyceride lipase and hormone-sensitive lipase to lipolysis in hMADS adipocytes. J. Biol. Chem. 284(27), 18282-18291 (2009).
33. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8(11), 1288-1295 (2002). (Pubitemid 35373562)
34. Ran J, Hirano T, Fukui T, et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55(4), 478-488 (2006).
35. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell Biol. 35(6), 807-825 (2003). (Pubitemid 36379323)
36. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell Biol. 24(12), 5434-5446 (2004). (Pubitemid 38738176)
37. Rask-Madsen C, Dominguez H, Ihlemann N, et al. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108(15), 1815-1821 (2003). (Pubitemid 37296090)
38. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
39. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371(9628), 1927-1935 (2008).
40. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J. Clin. Endocrinol. Metab. 86(7), 3257-3265 (2001). (Pubitemid 32674120)
41. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in Type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 26(2), 417-422 (2006). (Pubitemid 43732209)
42. Begonja AJ, Gambaryan S, Geiger J, et al. Platelet NAD(P)H-oxidase- generated ROS production regulates alpha IIb beta 3-integrin activation independent of the NO/cGMP pathway. Blood 106(8), 2757-2760 (2005). (Pubitemid 41510751)
43. Eringa EC, Bakker W, Smulders YM, et al. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 14(4-5), 389-402 (2007). (Pubitemid 47050030)
44. Meijer RI, Serne EH, Smulders YM, et al. Perivascular adipose tissue and its role in Type 2 diabetes and cardiovascular disease. Curr. Diab. Rep. 11(3), 211-217 (2011).
45. Yudkin JS, Eringa E, Stehouwer CD. 'Vasocrine' signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365(9473), 1817-1820 (2005). (Pubitemid 40744663)
46. Djaberi R, Schuijf JD, van Werkhoven JM, et al. Relation of epicardial adipose tissue to coronary atherosclerosis. Am. J. Cardiol. 102(12), 1602-1607 (2008).
47. Steinberg D. Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin. Mol. Nutr. Food Res. 49(11), 995-998 (2005). (Pubitemid 41735560)
48. Ashraf MZ, Kar NS, Podrez EA. Oxidized phospholipids: biomarker for cardiovascular diseases. Int. J. Biochem. Cell Biol. 41(6), 1241-1244 (2009).
49. Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr. Opin. Immunol. 14(1), 123-128 (2002). (Pubitemid 34085116)
50. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116(7), 1784-1792 (2006). (Pubitemid 44033298)
51. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 26(8), 2442-2450 (2003). (Pubitemid 36993340)
52. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100(25), 2473-2476 (1999). (Pubitemid 30005109)
53. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103(8), 1057-1063 (2001). (Pubitemid 32200177)
54. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of Type 2 diabetes in the Pima Indian population. Lancet 360(9326), 57-58 (2002). (Pubitemid 34756495)
55. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291(14), 1730-1737 (2004). (Pubitemid 38489895)
56. Lawlor DA, Davey SG, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J. Clin. Endocrinol. Metab. 90(10), 5677-5683 (2005). (Pubitemid 41415475)
57. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114(7), 623-629 (2006). (Pubitemid 44252303)
58. Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with Type 2 diabetes. Diabetes 54(2), 534-539 (2005).
59. Lee AK, Bishop JR. Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. Pharmacogenomics 12(7), 999-1016 (2011).
60. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269(5223), 546-549 (1995).
61. Morioka T, Asilmaz E, Hu J, et al. Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J. Clin. Invest. 117(10), 2860-2868 (2007). (Pubitemid 47529616)
62. Kieffer TJ, Habener JF. The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am. J. Physiol. Endocrinol. Metab. 278(1), E1-E14 (2000). (Pubitemid 30101914)
63. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189(1), 47-60 (2006). (Pubitemid 44441296)
64. Iikuni N, Lam QL, Lu L, Matarese G, La CA. Leptin and inflammation. Curr. Immunol. Rev. 4(2), 70-79 (2008).
65. Sundell J, Huupponen R, Raitakari OT, Nuutila P, Knuuti J. High serum leptin is associated with attenuated coronary vasoreactivity. Obes. Res. 11(6), 776-782 (2003). (Pubitemid 41151604)
66. Kajikawa Y, Ikeda M, Takemoto S, et al. Association of circulating levels of leptin and adiponectin with metabolic syndrome and coronary heart disease in patients with various coronary risk factors. Int. Heart J. 52(1), 17-22 (2011).
67. Soderberg S, Zimmet P, Tuomilehto J, et al. Leptin predicts the development of diabetes in Mauritian men, but not women: a population-based study. Int. J. Obes. (Lond.) 31(7), 1126-1133 (2007). (Pubitemid 46987769)
68. Sattar N, Wannamethee G, Sarwar N, et al. Leptin and coronary heart disease: prospective study and systematic review. J. Am. Coll. Cardiol. 53(2), 167-175 (2009).
69. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 104(25), 3052-3056 (2001). (Pubitemid 34014056)
70. Kim SK, Kim HJ, Ahn CW, et al. Hyperleptinemia as a robust risk factor of coronary artery disease and metabolic syndrome in Type 2 diabetic patients. Endocr. J. 55(6), 1085-1092 (2008).
71. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in Type 2 diabetes. J. Clin. Endocrinol. Metab. 89(8), 3872-3878 (2004). (Pubitemid 39071487)
72. D'Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia 50(4), 840-849 (2007). (Pubitemid 46355815)
73. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 107(3), 391-397 (2003).
74. Schulze MB, Rimm EB, Li T, et al. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27(4), 889-894 (2004). (Pubitemid 38420210)
75. Anand SS, Yusuf S. C-reactive protein is a bystander of cardiovascular disease. Eur. Heart J. 31(17), 2092-2096 (2010).
76. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 145(2), 375-379 (1999). (Pubitemid 29359147)
77. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr. Opin. Lipidol. 20(3), 182-189 (2009).
78. Koike T, Kitajima S, Yu Y, et al. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation 120(21), 2088-2094 (2009).
79. Trion A, de Maat MP, Jukema JW, et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler. Thromb. Vasc. Biol. 25(8), 1635-1640 (2005). (Pubitemid 41098933)
80. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302(1), 37-48 (2009).
81. Kaptoge S, Di AE, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375(9709), 132-140 (2010).
82. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350(14), 1387-1397 (2004). (Pubitemid 38419992)
83. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann. Intern. Med. 145(1), 21-29 (2006). (Pubitemid 46780601)
84. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297(6), 611-619 (2007).
85. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
86. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 112(9), 1289-1295 (2005). (Pubitemid 41266723)
87. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 8, 253-278 (1990). (Pubitemid 20135628)
88. Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 5(12), e14328 (2010).
89. Loppnow H, Werdan K, Buerke M. Vascular cells contribute to atherosclerosis by cytokine-and innate-immunity-related inflammatory mechanisms. Innate Immun. 14(2), 63-87 (2008).
90. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 88(4), 1379-1406 (2008).
91. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb. Haemost. 102(2), 215-222 (2009).
92. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 5(4), e78 (2008).
93. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing Type 2 diabetes in women. Diabetes 53(3), 693-700 (2004). (Pubitemid 38270639)
94. Lowe GD, Rumley A, McMahon AD, et al. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 24(8), 1529-1534 (2004). (Pubitemid 39050452)
95. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med. 351(25), 2599-2610 (2004). (Pubitemid 39628581)
96. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch. Intern. Med. 166(13), 1368-1373 (2006). (Pubitemid 44036348)
97. Saremi A, Moritz TE, Anderson RJ, et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 33(12), 2642-2647 (2010).
98. Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in Type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J. Am. Coll. Cardiol. 50(23), 2218-2225 (2007). (Pubitemid 350166815)
99. Herder C, Schottker B, Rothenbacher D, et al. Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study. Atherosclerosis 216(1), 244-247 (2011).
100. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol. Ther. 127(3), 295-314 (2010).
101. Varfolomeev E, Vucic D. (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 7(11), 1511-1521 (2008). (Pubitemid 351881313)
102. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 48(4), 751-762 (2007).
103. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87(1), 99-109 (2005). (Pubitemid 40298772)
104. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl Acad. Sci. USA 91(11), 4854-4858 (1994). (Pubitemid 24177748)
105. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 285(3), E527-E533 (2003). (Pubitemid 37010830)
106. Van der Poll T, Romijn JA, Endert E, et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am. J. Physiol. 261(4 Pt 1), E457-E465 (1991).
107. Gao X, Belmadani S, Picchi A, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 115(2), 245-254 (2007). (Pubitemid 46105724)
108. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ. Res. 99(1), 69-77 (2006). (Pubitemid 44297057)
109. Lei L, Xiong Y, Chen J, et al. TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J. Lipid Res. 50(6), 1057-1067 (2009).
110. Pischon T, Hu FB, Rexrode KM, et al. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 197(1), 392-399 (2008). (Pubitemid 351273261)
111. Safranow K, Dziedziejko V, Rzeuski R, et al. Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens 74(5), 386-392 (2009).
112. Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 111(7), 863-870 (2005). (Pubitemid 40279887)
113. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108(19), 2317-2322 (2003). (Pubitemid 37413536)
114. Aukrust P, Halvorsen B, Yndestad A, et al. Chemokines and cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 28(11), 1909-1919 (2008). nSurvey of the available studies on chemokines and the predictive value of chemokines with CHD or subclinical atherosclerosis.
115. Kraaijeveld AO, de Jager SC, van Berkel TJ, Biessen EA, Jukema JW. Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? Curr. Pharm. Des. 13(10), 1039-1052 (2007). (Pubitemid 46705204)
116. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol. 28(11), 1897-1908 (2008).
117. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394(6696), 894-897 (1998). (Pubitemid 28410911)
118. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2(2), 275-281 (1998). (Pubitemid 128373654)
119. Canoui-Poitrine F, Luc G, Mallat Z, et al. Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME Study. Neurology 77(12), 1165-1173 (2011).
120. van Wijk DF, van Leuven SI, Sandhu MS, et al. Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 30(7), 1460-1466 (2010).
121. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc. Drugs Ther. 23(1), 73-83 (2009).
122. Rosenson RS. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Curr. Opin. Lipidol. 21(6), 473-480 (2010).
123. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375(9725), 1536-1544 (2010).
124. Kardys I, Oei HH, van der Meer IM, et al. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler. Thromb. Vasc. Biol. 26(3), 631-636 (2006).
125. Kinney GL, Snell-Bergeon JK, Maahs DM, et al. Lipoprotein-associated phospholipase A activity predicts progression of subclinical coronary atherosclerosis. Diabetes Technol. Ther. 13(3), 381-387 (2011).
126. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) biomarker project. Circulation 121(22), 2388-2397 (2010).
127. Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with Type 2 diabetes. Diabetes 59(5), 1239-1243 (2010).
128. Ortiz A, Sanz AB, Munoz GB, et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev. 20(3), 251-258 (2009).
129. Tiller G, Fischer-Posovszky P, Laumen H, et al. Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. Endocrinology 150(12), 5373-5383 (2009).
130. Feng F, Wang L, Albanese N, Holmes A, Xia P. Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes. Endocrinology 149(4), 1505-1513 (2008). (Pubitemid 351468332)
131. Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin. J. Am. Soc. Nephrol. 6(4), 785-792 (2011).
132. Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 343(1), 237-249 (2011).
133. Bassi N, Zampieri S, Ghirardello A, et al. Pentraxins, anti-pentraxin antibodies, and atherosclerosis. Clin. Rev. Allergy Immunol. 37(1), 36-43 (2009).
134. Osorio-Conles O, Guitart M, Chacon MR, et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am. J. Physiol. Endocrinol. Metab. 301(6), E1254-E1261 (2011).
135. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler. Thromb. Vasc. Biol. 27(1), 161-167 (2007). (Pubitemid 46360394)
136. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 29(4), 594-599 (2009).
137. Garcia-Garcia HM, Klauss V, Gonzalo N, et al. Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis. Int. J. Cardiovasc. Imaging doi:10.1007/ s10554-011-9882-6 (2011) (Epub ahead of print).